Importance:
Active surveillance (AS) is now recognized as the preferred management option for most low-risk prostate cancers to minimize risks of overtreatment. Despite increasing use of AS in the US, wide regional variability has been observed, and these regional variations in contemporary practice have not been well described.
Objective:
To explore variations between county and Surveillance, Epidemiology, and End Results (SEER) regions in AS in the US.
Design, Setting, And Participants:
A cohort study using the SEER Prostate with Watchful Waiting (WW) database linked to the County Area Health Resource File for detailed county-level demographics and physician distribution data was conducted from January 2010 to December 2015. Analysis was performed in October 2020. A total of 79 825 men with clinically localized, low-risk prostate cancer eligible for AS or WW were included.
Exposures:
Multiple patient-, county-, and SEER region-level factors, including age, year of diagnosis, county-level densities of urologists, radiation oncologists, primary care physicians, and SEER registry region.
Main Outcomes And Measures:
Use of AS or WW as the initial reported treatment strategy were noted. Hierarchical mixed-effect logistic regression models were used to evaluate clustered random regional variation on use of AS or WW. Temporal trends by year in proportions of initial treatment type, as well as county-level local variation, were also estimated.
Results:
Of 79 825 men (mean [SD] age, 62.8 [7.6] years, 11 292 [14.1%] non-Hispanic Black, 7506 [9.4%] Hispanic) with low-risk prostate cancer, the mean annualized percent increase in AS rates from 2010 to 2015 ranged from 6.3% in New Mexico to 81.0% in New Jersey. Differences across SEER regions accounted for 17% of the total variation in AS. Increasing age (51-60 years: odds ratio [OR], 1.33; 95% CI, 1.21-1.46; 61-70 years: OR, 1.86; 95% CI, 1.70-2.04; 71-80 years: OR, 2.26; 95% CI, 2.05-2.50) was associated with greater odds of AS. Hispanic ethnicity (OR, 0.79; 95% CI, 0.74-0.85), T category (OR, 0.79; 95% CI, 0.73-0.84), and Medicaid enrollment (OR, 0.73; 95% CI, 0.66-0.81) were associated with lower odds of AS. Black race, county-level socioeconomic factors (household income, educational level, and city type), and specialist densities were not associated with AS use.
Conclusions And Relevance:
In this US cohort study based on the SEER-WW database, although the use of AS increased, considerable practice variation appeared to be associated with geographic location, but use of AS was not associated with Black race, specialty professional density, or socioeconomic factors. This small area variation underlies the broader national trends in AS practice and may inform policies aimed at continuing to affect risk-appropriate care for men throughout the US.
Citing Articles
The burden of prostate cancer in the North Africa and Middle East Region from 1990 to 2021.
Safiri S, Shamekh A, Hassanzadeh K, Fazlollahi A, Sullman M, Raeisi M
Sci Rep. 2025; 15(1):1853.
PMID: 39805870
PMC: 11731011.
DOI: 10.1038/s41598-024-83840-3.
Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer.
Srivastava A, Kaufman S, Shay A, Oerline M, Liu X, Van Til M
JAMA Netw Open. 2025; 8(1):e2453658.
PMID: 39775806
PMC: 11795379.
DOI: 10.1001/jamanetworkopen.2024.53658.
County-level racial disparities in prostate cancer-specific mortality from 2005 to 2020.
Washington Iii S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J
JNCI Cancer Spectr. 2024; 8(6).
PMID: 39495143
PMC: 11631307.
DOI: 10.1093/jncics/pkae109.
Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively.
Adetunji A, Venishetty N, Gombakomba N, Jeune K, Smith M, Winer A
Curr Urol Rep. 2024; 25(10):253-260.
PMID: 38869692
DOI: 10.1007/s11934-024-01219-3.
Spatial characteristics of non-communicable diseases and their associations to social conditions in a large urban cohort in Germany-Results from the Hamburg City Health Study.
Andrees V, Bei der Kellen R, Augustin M, Gallinat J, Harth V, Hoven H
PLoS One. 2024; 19(4):e0301475.
PMID: 38593150
PMC: 11003678.
DOI: 10.1371/journal.pone.0301475.
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016.
Desmond C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A
Prostate Cancer Prostatic Dis. 2024; .
PMID: 38555410
DOI: 10.1038/s41391-024-00822-2.
Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
Guan A, Santiago-Rodriguez E, Chung B, Shim J, Allen L, Kuo M
BMC Cancer. 2023; 23(1):1191.
PMID: 38053037
PMC: 10696696.
DOI: 10.1186/s12885-023-11679-4.
Active surveillance should be considered for select men with Grade Group 2 prostate cancer.
Pekala K, Bergengren O, Eastham J, Carlsson S
BMC Urol. 2023; 23(1):152.
PMID: 37777716
PMC: 10541702.
DOI: 10.1186/s12894-023-01314-6.
Explainable ML models for a deeper insight on treatment decision for localized prostate cancer.
Han J, Lee S, Lee B, Baek O, Washington 3rd S, Herlemann A
Sci Rep. 2023; 13(1):11532.
PMID: 37460568
PMC: 10352331.
DOI: 10.1038/s41598-023-38162-1.
Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes.
Ahlberg M, Garmo H, Holmberg L, Bill-Axelson A
Eur Urol Open Sci. 2023; 52:166-173.
PMID: 37284040
PMC: 10240510.
DOI: 10.1016/j.euros.2023.04.006.
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [F]DCFPyL PET/CT in prostate cancer men.
Subramanian K, Martinez J, Huicochea Castellanos S, Ivanidze J, Nagar H, Nicholson S
Sci Rep. 2023; 13(1):8321.
PMID: 37221397
PMC: 10205741.
DOI: 10.1038/s41598-023-35567-w.
Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?.
Spratte B, Tan H, Zambrano I, Basak R, Filson C, Jacobs B
Urol Oncol. 2023; 41(7):323.e17-323.e25.
PMID: 37149430
PMC: 11228925.
DOI: 10.1016/j.urolonc.2023.04.006.
Observation, Radiotherapy, or Radical Prostatectomy for Localized Prostate Cancer: Survival Analysis in the United States.
Han J, Herlemann A, Washington S, Lonergan P, Carroll P, Cooperberg M
World J Mens Health. 2023; 41(4):940-950.
PMID: 37118954
PMC: 10523124.
DOI: 10.5534/wjmh.220151.
Employment and Labor Force Participation Among Prostate Cancer Survivors.
Howard D, Hall I
Urol Pract. 2023; 10(2):179-185.
PMID: 37103405
PMC: 11003821.
DOI: 10.1097/UPJ.0000000000000380.
A vision for closing the evidence-practice gap in the management of low-grade prostate cancer.
Leapman M, Loeb S, Cooperberg M, Catalona W, Gaylis F
JNCI Cancer Spectr. 2023; 7(2).
PMID: 37101361
PMC: 10133397.
DOI: 10.1093/jncics/pkad028.
Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies.
Bharmjeet , Das A
Cancer Rep (Hoboken). 2023; 6 Suppl 1:e1807.
PMID: 36971312
PMC: 10440846.
DOI: 10.1002/cnr2.1807.
Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol.
Thankapannair V, Keates A, Barrett T, Gnanapragasam V
Eur Urol Open Sci. 2023; 49:15-22.
PMID: 36874604
PMC: 9975013.
DOI: 10.1016/j.euros.2022.12.013.
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg M, Meeks W, Fang R, Gaylis F, Catalona W, Makarov D
JAMA Netw Open. 2023; 6(3):e231439.
PMID: 36862409
PMC: 9982696.
DOI: 10.1001/jamanetworkopen.2023.1439.
Prostate cancer grade migration and facility-level treatment trends for grade group 1 disease.
Borregales L, Tzeng M, Ramaswamy A, Gu X, Davuluri M, Nagar H
JNCI Cancer Spectr. 2023; 7(2).
PMID: 36840651
PMC: 10133398.
DOI: 10.1093/jncics/pkad018.
The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer.
Posielski N, Shanmuga S, Ho O, Jiang J, Elsamanoudi S, Speir R
Prostate Cancer Prostatic Dis. 2022; 26(2):415-420.
PMID: 36357592
DOI: 10.1038/s41391-022-00608-4.